Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis

Caldwell, Brent; Aldington, Sarah; Weatherall, Mark; Shirtcliffe, Philippa; Beasley, Richard

doi:10.1258/jrsm.99.3.132

Cited by 174 publications

(101 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the withdrawal of rofecoxib and valdecoxib, celecoxib remained on the market in the United States, and research surrounding the safety of NSAIDs continued. 65,66 Many experts were not convinced that the cardiovascular effects of rofecoxib represented a class effect. 54,67 In addition, the debate continued regarding the association between COX-1 and COX-2 selectivity and risks, as well as factors that modulate drug response.…”

Section: Nsaids: Cox-2 Versus Cox-1 Selectivitymentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

and completed residency training in physical medicine and rehabilitation at The Ohio State University. Dr. Atchison has been in practice at academic medical centers for more than 20 years, serving on the faculty at the University of Kentucky and University of Florida before his appointment at Northwestern University. A recognized teacher and researcher in the field of pain management and rehabilitation, he has presented courses, lectures, and workshops nationally and internationally on pharmacological and nonpharmacological therapies, care of spinal injuries, and spinal manipulation. Dr. Atchison has led and participated in many research projects, including several funded by the National Institutes of Health. He has authored numerous research papers and book chapters, and he serves as a peer reviewer for the Archives of Physical Medicine and Rehabilitation. He has been a member of the editorial boards of the Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S14 Multitarget Drugs S15 Conclusions S15 References Target AudiencesThis CME/CE activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and nurses. Learning Objectives• Assess patient-specific risk factors in selecting NSAIDs for mild-to-moderate musculoskeletal pain • Incorporate risk/benefit analysis in decision making about NSAID use • Use evidence-based guidelines for selecting NSAID therapy and applying strategies to prevent complications • Evaluate the efficacy, safety, and pharmacological profile of new and emerging NSAID formulations Funding This supplement was funded by an independent educational grant to PRIME Education, Inc. (PRIME) from Iroko Pharmaceuticals, LLC. Accreditation StatementsIn support of improving patient care, PRIME Education, Inc. (PRIME) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing educat...

show abstract

Section: Nsaids: Cox-2 Versus Cox-1 Selectivitymentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

show abstract

“…De fleste som har undersøkt mulige sammenhenger mellom dose ikke-steroid antiinflammatorisk middel og økt risiko for kardiovaskulaere hendelser, har påvist en dose-effektsammenheng (7,13,17,18,31). Unntaket er naproksen, hvor risikoøkningen har vaert fravaerende (tab 2), og en metaanalyse (6) der man ikke kunne påvise at den vaskulaere risikoen til verken selektive COX-2-hemmere eller tradisjonelle ikke-steroide antiinflammatoriske midler var doseavhengig.…”

Section: Er Risikoen Avhengig Av Dose Behandlingsvarighet Eller Andrunclassified

Hjerte, smerte – kardiovaskulær sikkerhet og ikke-steroide antiinflammatoriske midler

Møllersen¹,

Norgård²,

Spigset³

et al. 2015

Tidsskriftet

View full text Add to dashboard Cite

“…Nonsteroidal anti-inflammatory drugs are associated with well-known risks of gastrointestinal (Boers et al, 2007;Gabriel et al, 1991;, cardiovascular (Antman et al, 2007;Caldwell et al, 2006;Juni et al, 2004;Kearney et al, 2006;Motsko et al, 2006), and renal (Barkin & Buvanendran, 2004;Evans et al, 1995) adverse events. Hepatic adverse events have been reported infrequently (Rostom et al, 2005;Rubenstein & Laine, 2004), and are certainly less common than with acetaminophen.…”

Section: Nonsteroidal Anti-inflammatory Drugsmentioning

confidence: 99%

“…Acetaminophen is a welltolerated first-line pharmacotherapy but has limited efficacy (Zhang et al, 2010) and highdose, long-term use is associated with hepatic toxicity (Watkins et al, 2006). NSAIDs have better efficacy than acetaminophen but have well-known risks of gastrointestinal (Boers et al, 2007;Gabriel et al, 1991;, cardiovascular (Antman et al, 2007;Caldwell et al, 2006;Kearney et al, 2006;Motsko et al, 2006), and other systemic adverse effects that increase with age, dose, and duration of use.…”

Section: Introductionmentioning

confidence: 99%

Pharmacotherapy for Chronic Low Back Pain

Peniston¹

2012

Low Back Pain Pathogenesis and Treatment

View full text Add to dashboard Cite

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis

Abstract: The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.

Cited by 174 publications

References 25 publications

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Hjerte, smerte – kardiovaskulær sikkerhet og ikke-steroide antiinflammatoriske midler

Pharmacotherapy for Chronic Low Back Pain

Contact Info

Product

Resources

About